Grant for Cancer Treatment Research Announced By Hochul
Sep 5, 2012 Issues: Health Care, Jobs and Economy, Local Issues
Will Allow for Testing of Pancreatic Cancer Treatment
WILLIAMSVILLE, N.Y. – Today, Representative Kathy Hochul (NY-26) announced the National Cancer Institute (NCI) has awarded Buffalo BioLabs, LLC a $300,000 Phase I Small Business Technology Transfer (STTR) grant for pancreatic cancer research.
“I am pleased to announce this critical grant to aid in the fight against pancreatic cancer. The National Cancer Institute’s investment in Buffalo BioLabs will not only fund cutting edge cancer treatment, but also benefit the life sciences industry in Western New York. I will continue to advocate for further STTR investment in our region to foster innovation and ensure continued support for small businesses,” said Rep. Hochul.
"We're so grateful for this support from the STTR program," said Dr. Katerina Gurova, a researcher in Roswell Park's Department of Cell Stress Biology, who will lead the research effort. "These funds will help us to advance promising research about curaxins, which target several important pathways involved in development of pancreatic cancer."
Recently, Rep. Hochul has held roundtable discussions in Amherst and Rochester about the high tech industry and potential for economic growth through research and development. Hochul has worked to help life science and high tech businesses grow through her support of the Research and Development tax credit and her school to work initiative, the Workforce-Ready Educate America Act, as well as her Revitalizing our Economy through Business, Infrastructure, and Local Development (REBUILD) Western New York plan and her Make It In America plan.Today, Representative Kathy Hochul (NY-26) announced the National Cancer Institute (NCI) has awarded Buffalo BioLabs, LLC a $300,000 Phase I Small Business Technology Transfer (STTR) grant for pancreatic cancer research.
Buffalo BioLabs is a wholly owned subsidiary of Cleveland BioLabs Inc. (CBLI), which relocated from Ohio to Buffalo in 2007 to Roswell Park Cancer Institute. The move brought more than 50 advanced research jobs to Western New York and launched an ongoing drug-development and research partnership between Roswell Park and CBLI.
